Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Assets: 2019-2024

Historic Current Assets for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $1.5 billion.

  • Avidity Biosciences' Current Assets rose 21.22% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 21.22%. This contributed to the annual value of $1.5 billion for FY2024, which is 152.29% up from last year.
  • As of FY2024, Avidity Biosciences' Current Assets stood at $1.5 billion, which was up 152.29% from $611.3 million recorded in FY2023.
  • Avidity Biosciences' Current Assets' 5-year high stood at $1.5 billion during FY2024, with a 5-year trough of $331.7 million in FY2020.
  • Moreover, its 3-year median value for Current Assets was $622.9 million (2022), whereas its average is $925.5 million.
  • In the last 5 years, Avidity Biosciences' Current Assets surged by 246.67% in 2020 and then dropped by 1.87% in 2023.
  • Over the past 5 years, Avidity Biosciences' Current Assets (Yearly) stood at $331.7 million in 2020, then climbed by 23.96% to $411.1 million in 2021, then surged by 51.52% to $622.9 million in 2022, then decreased by 1.87% to $611.3 million in 2023, then spiked by 152.29% to $1.5 billion in 2024.